The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.
Identifieur interne : 000048 ( Main/Corpus ); précédent : 000047; suivant : 000049The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.
Auteurs : Nijad Bakhshaliyev ; Ramazan ÖzdemirSource :
- Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc [ 1542-474X ] ; 2021.
Abstract
BACKGROUND
Since there was no proven treatment of coronavirus disease 2019 (COVID-19), hydroxychloroquine-azithromycin (HCQ-AZM) combination is being used in different countries as a treatment option. Many controversies exist related to the safety and effectiveness of this combination, and questions about how HCQ-AZM combination affects the ventricular repolarization are still unknown.
OBJECTIVE
The aim of the study was to show whether the hydroxychloroquine-azithromycin (HCQ-AZM) combination prolonged Tpeak-to-end (TpTe) duration and TpTe/QT interval ratio or not.
METHODS
One hundred and twenty-six consequent COVID-19(+) patients meeting the study criteria were enrolled in this study. Baseline ECGs were obtained immediately after hospitalization and before commencing the HCQ-AZM combination. On-treatment ECG was obtained 24-48 hr after the loading dose of HCQ/AZM. ECG parameters including PR interval, QRS duration, QT interval, QTc interval, TpTe duration, and TpTe/QT interval ratio were assessed. Demographic and laboratory findings were collected from an electronic recording system.
RESULTS
ECGs of 126 COVID-19(+) patients who received HCQ-AZM combination were assessed. Mean baseline QTc (by Fridericia formula), TpTe, and TpTe/QT ratio were 420.0 ± 26.5 ms, 82.43 ± 9.77 ms, and 0.22 ± 0.02, respectively. On-treatment QTc, TpTe and TpTe/QT ratio were 425.7 ± 27.18 ms, 85.17 ± 11.17 ms, and 0.22 ± 0.03, respectively. No statistically significant acute impacts of HCQ-AZM combination on TpTe duration and TpTe/QT interval ratio were observed compared with baseline values. No ventricular tachycardia/fibrillation and the significant conduction delays were seen during in-hospital follow-up.
CONCLUSION
HCQ-AZM combination increased TpTe duration. However, no significant impact on TpTe/QT interval ratio was observed.
DOI: 10.1111/anec.12846
PubMed: 33956361
Links to Exploration step
pubmed:33956361Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.</title><author><name sortKey="Bakhshaliyev, Nijad" sort="Bakhshaliyev, Nijad" uniqKey="Bakhshaliyev N" first="Nijad" last="Bakhshaliyev">Nijad Bakhshaliyev</name><affiliation><nlm:affiliation>Bezmialem Vakif University, Istanbul, Turkey.</nlm:affiliation></affiliation></author><author><name sortKey="Ozdemir, Ramazan" sort="Ozdemir, Ramazan" uniqKey="Ozdemir R" first="Ramazan" last="Özdemir">Ramazan Özdemir</name><affiliation><nlm:affiliation>Bezmialem Vakif University, Istanbul, Turkey.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33956361</idno><idno type="pmid">33956361</idno><idno type="doi">10.1111/anec.12846</idno><idno type="wicri:Area/Main/Corpus">000048</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000048</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.</title><author><name sortKey="Bakhshaliyev, Nijad" sort="Bakhshaliyev, Nijad" uniqKey="Bakhshaliyev N" first="Nijad" last="Bakhshaliyev">Nijad Bakhshaliyev</name><affiliation><nlm:affiliation>Bezmialem Vakif University, Istanbul, Turkey.</nlm:affiliation></affiliation></author><author><name sortKey="Ozdemir, Ramazan" sort="Ozdemir, Ramazan" uniqKey="Ozdemir R" first="Ramazan" last="Özdemir">Ramazan Özdemir</name><affiliation><nlm:affiliation>Bezmialem Vakif University, Istanbul, Turkey.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc</title><idno type="eISSN">1542-474X</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Since there was no proven treatment of coronavirus disease 2019 (COVID-19), hydroxychloroquine-azithromycin (HCQ-AZM) combination is being used in different countries as a treatment option. Many controversies exist related to the safety and effectiveness of this combination, and questions about how HCQ-AZM combination affects the ventricular repolarization are still unknown.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>The aim of the study was to show whether the hydroxychloroquine-azithromycin (HCQ-AZM) combination prolonged Tpeak-to-end (TpTe) duration and TpTe/QT interval ratio or not.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>One hundred and twenty-six consequent COVID-19(+) patients meeting the study criteria were enrolled in this study. Baseline ECGs were obtained immediately after hospitalization and before commencing the HCQ-AZM combination. On-treatment ECG was obtained 24-48 hr after the loading dose of HCQ/AZM. ECG parameters including PR interval, QRS duration, QT interval, QTc interval, TpTe duration, and TpTe/QT interval ratio were assessed. Demographic and laboratory findings were collected from an electronic recording system.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>ECGs of 126 COVID-19(+) patients who received HCQ-AZM combination were assessed. Mean baseline QTc (by Fridericia formula), TpTe, and TpTe/QT ratio were 420.0 ± 26.5 ms, 82.43 ± 9.77 ms, and 0.22 ± 0.02, respectively. On-treatment QTc, TpTe and TpTe/QT ratio were 425.7 ± 27.18 ms, 85.17 ± 11.17 ms, and 0.22 ± 0.03, respectively. No statistically significant acute impacts of HCQ-AZM combination on TpTe duration and TpTe/QT interval ratio were observed compared with baseline values. No ventricular tachycardia/fibrillation and the significant conduction delays were seen during in-hospital follow-up.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>HCQ-AZM combination increased TpTe duration. However, no significant impact on TpTe/QT interval ratio was observed.</p></div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">33956361</PMID><DateRevised><Year>2021</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1542-474X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>May</Month><Day>06</Day></PubDate></JournalIssue><Title>Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc</Title><ISOAbbreviation>Ann Noninvasive Electrocardiol</ISOAbbreviation></Journal><ArticleTitle>The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.</ArticleTitle><Pagination><MedlinePgn>e12846</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/anec.12846</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since there was no proven treatment of coronavirus disease 2019 (COVID-19), hydroxychloroquine-azithromycin (HCQ-AZM) combination is being used in different countries as a treatment option. Many controversies exist related to the safety and effectiveness of this combination, and questions about how HCQ-AZM combination affects the ventricular repolarization are still unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of the study was to show whether the hydroxychloroquine-azithromycin (HCQ-AZM) combination prolonged Tpeak-to-end (TpTe) duration and TpTe/QT interval ratio or not.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred and twenty-six consequent COVID-19(+) patients meeting the study criteria were enrolled in this study. Baseline ECGs were obtained immediately after hospitalization and before commencing the HCQ-AZM combination. On-treatment ECG was obtained 24-48 hr after the loading dose of HCQ/AZM. ECG parameters including PR interval, QRS duration, QT interval, QTc interval, TpTe duration, and TpTe/QT interval ratio were assessed. Demographic and laboratory findings were collected from an electronic recording system.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">ECGs of 126 COVID-19(+) patients who received HCQ-AZM combination were assessed. Mean baseline QTc (by Fridericia formula), TpTe, and TpTe/QT ratio were 420.0 ± 26.5 ms, 82.43 ± 9.77 ms, and 0.22 ± 0.02, respectively. On-treatment QTc, TpTe and TpTe/QT ratio were 425.7 ± 27.18 ms, 85.17 ± 11.17 ms, and 0.22 ± 0.03, respectively. No statistically significant acute impacts of HCQ-AZM combination on TpTe duration and TpTe/QT interval ratio were observed compared with baseline values. No ventricular tachycardia/fibrillation and the significant conduction delays were seen during in-hospital follow-up.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">HCQ-AZM combination increased TpTe duration. However, no significant impact on TpTe/QT interval ratio was observed.</AbstractText><CopyrightInformation>© 2021 The Authors. Annals of Noninvasive Electrocardiology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bakhshaliyev</LastName><ForeName>Nijad</ForeName><Initials>N</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8116-7846</Identifier><AffiliationInfo><Affiliation>Bezmialem Vakif University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Özdemir</LastName><ForeName>Ramazan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bezmialem Vakif University, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Noninvasive Electrocardiol</MedlineTA><NlmUniqueID>9607443</NlmUniqueID><ISSNLinking>1082-720X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Tpeak-to-end</Keyword><Keyword MajorTopicYN="N">azithromycin</Keyword><Keyword MajorTopicYN="N">cardiac death</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">electrocardiography</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>02</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>01</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>03</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>6</Day><Hour>13</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33956361</ArticleId><ArticleId IdType="doi">10.1111/anec.12846</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Anderson, M. E., Al-Khatib, S. M., Roden, D. M., Califf, R. M., & Institute DCR. (2002). Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management. American Heart Journal, 144(5), 769-781. https://doi.org/10.1067/mhj.2002.125804</Citation></Reference><Reference><Citation>Antzelevitch, C., Di Diego, J. M., & Argenziano, M. (2017). Tpeak-Tend as a predictor of ventricular arrhythmogenesis. International Journal of Cardiology, 249, 75-76. https://doi.org/10.1016/j.ijcard.2017.09.005</Citation></Reference><Reference><Citation>Bakhshaliyev, N., Uluganyan, M., Enhos, A., Karacop, E., & Ozdemir, R. (2020). The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19 (+) patients. Journal of Electrocardiology, 62, 59-64. https://doi.org/10.1016/j.jelectrocard.2020.08.008</Citation></Reference><Reference><Citation>Bernardini, A., Ciconte, G., Negro, G., Rondine, R., Mecarocci, V., Viva, T., Santini, F., de Innocentiis, C., Giannelli, L., Witkowska, E., Locati, E. T., Castelvecchio, S., Marrocco-Trischitta, M. M., Vicedomini, G., Menicanti, L., & Pappone, C. (2020). Assessing QT interval in COVID-19 patients: Safety of Hydroxychloroquine-azithromycin combination regimen. International Journal of Cardiology, 324, 242-248. https://doi.org/10.1016/j.ijcard.2020.09.038</Citation></Reference><Reference><Citation>Bessière, F., Roccia, H., Delinière, A., Charrière, R., Chevalier, P., Argaud, L., & Cour, M. (2020). Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiology, 5(9), 1067. https://doi.org/10.1001/jamacardio.2020.1787</Citation></Reference><Reference><Citation>Çağdaş, M., Karakoyun, S., Rencüzoğulları, İ., Karabağ, Y., Yesin, M., Velibey, Y., Artaç, İ., İliş, D., Efe, S. Ç., Taşar, O., & Tanboğa, H. I. (2018). Assessment of the relationship between reperfusion success and T-peak to T-end interval in patients with ST elevation myocardial infarction treated with percutaneous coronary intervention. Anatolian Journal of Cardiology, 19(1), 50, https://doi.org/10.14744/AnatolJCardiol.2017.7949</Citation></Reference><Reference><Citation>Castro-Torres, Y., Robau, S. C., & Clara-Cuba, V. (2017). Tp-e interval and Tp-e/QTc ratio: New choices for risk stratification of arrhythmic events in patients with hypertrophic cardiomyopathy. The Anatolian Journal of Cardiology, 17(6), 493-493. https://doi.org/10.14744/AnatolJCardiol.2017.7865</Citation></Reference><Reference><Citation>Demidova, M., Carlson, J., Erlinge, D., Azarov, J., & Platonov, P. (2019). Prolonged Tpeak-Tend interval is associated with ventricular fibrillation during reperfusion in ST-elevation myocardial infarction. International Journal of Cardiology, 280, 80-83. https://doi.org/10.1016/j.ijcard.2019.01.008</Citation></Reference><Reference><Citation>Gupta, P., Patel, C., Patel, H., Narayanaswamy, S., Malhotra, B., Green, J. T., & Yan, G. X. (2008). Tp-e/QT ratio as an index of arrhythmogenesis. Journal of Electrocardiology, 41(6), 567-574. https://doi.org/10.1016/j.jelectrocard.2008.07.016</Citation></Reference><Reference><Citation>Kors, J. A., van Eck, H. J. R., & van Herpen, G. (2008). The meaning of the Tp-Te interval and its diagnostic value. Journal of Electrocardiology, 41(6), 575-580. https://doi.org/10.1016/j.jelectrocard.2008.07.030</Citation></Reference><Reference><Citation>Matzneller, P., Krasniqi, S., Kinzig, M., Sörgel, F., Hüttner, S., Lackner, E., Müller, M., & Zeitlinger, M. (2013). Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrobial Agents and Chemotherapy, 57(4), 1736-1742. https://doi.org/10.1128/AAC.02011-12</Citation></Reference><Reference><Citation>Mercuro, N. J., Yen, C. F., Shim, D. J., Maher, T. R., McCoy, C. M., Zimetbaum, P. J., & Gold, H. S. (2020). Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiology, 5(9), 1036. https://doi.org/10.1001/jamacardio.2020.1834</Citation></Reference><Reference><Citation>Munster, T., Gibbs, J. P., Shen, D., Baethge, B. A., Botstein, G. R., Caldwell, J., Dietz, F., Ettlinger, R., Golden, H. E., Lindsley, H., McLaughlin, G. E., Moreland, L. W., Roberts, W. N., Rooney, T. W., Rothschild, B., Sack, M., Sebba, A. I., Weisman, M., Welch, K. E., … Furst, D. E. (2002). Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 46(6), 1460-1469. https://doi.org/10.1002/art.10307</Citation></Reference><Reference><Citation>Opthof, T., Coronel, R., Wilms-Schopman, F. J., Plotnikov, A. N., Shlapakova, I. N., Danilo, P. Jr, Rosen, M. R., & Janse, M. J. (2007). Dispersion of repolarization in canine ventricle and the electrocardiographic T wave: Tp-e interval does not reflect transmural dispersion. Heart Rhythm: The Official Journal of the Heart Rhythm Society, 4(3), 341-348. https://doi.org/10.1016/j.hrthm.2006.11.022</Citation></Reference><Reference><Citation>Porthan, K., Viitasalo, M., Toivonen, L., Havulinna, A. S., Jula, A., Tikkanen, J. T., Väänänen, H., Nieminen, M. S., Huikuri, H. V., Newton-Cheh, C., Salomaa, V., & Oikarinen, L. (2013). Predictive value of electrocardiographic T-wave morphology parameters and T-wave peak to T-wave end interval for sudden cardiac death in the general population. Circulation: Arrhythmia and Electrophysiology, 6(4), 690-696.</Citation></Reference><Reference><Citation>Pruchnicki, S., Good, T., & Walson, P. (1996). Severe hydroxychloroquine poisoning reversed with diazepam. Journal of Toxicology Clinical Toxicology, 33, 582.</Citation></Reference><Reference><Citation>Rosenthal, T. M., Masvidal, D., Abi Samra, F. M., Bernard, M. L., Khatib, S., Polin, G. M., Rogers, P. A., Xue, J. Q., & Morin, D. P. (2018). Optimal method of measuring the T-peak to T-end interval for risk stratification in primary prevention. Ep Europace, 20(4), 698-705. https://doi.org/10.1093/europace/euw430</Citation></Reference><Reference><Citation>Rosenthal, T. M., Stahls, P. F. 3rd, Abi Samra, F. M., Bernard, M. L., Khatib, S., Polin, G. M., Xue, J. Q., & Morin, D. P. (2015). T-peak to T-end interval for prediction of ventricular tachyarrhythmia and mortality in a primary prevention population with systolic cardiomyopathy. Heart Rhythm: The Official Journal of the Heart Rhythm Society, 12(8), 1789-1797. https://doi.org/10.1016/j.hrthm.2015.04.035</Citation></Reference><Reference><Citation>Saha, B. K., Bonnier, A., & Chong, W. (2020). Antimalarials as antivirals for COVID-19: Believe it or not!. The American Journal of the Medical Sciences, 360(6), 618-630. https://doi.org/10.1016/j.amjms.2020.08.019</Citation></Reference><Reference><Citation>Tse, G., Gong, M., Li, C. K. H., Leung, K. S. K., Georgopoulos, S., Bazoukis, G., Letsas, K. P., Sawant, A. C., Mugnai, G., Wong, M. C. S., Yan, G. X., Brugada, P., Chierchia, G. B., de Asmundis, C., Baranchuk, A., Liu, T., & International Health Informatics Study (IHIS) Network. (2018). Tpeak-Tend, Tpeak-Tend/QT ratio and Tpeak-Tend dispersion for risk stratification in Brugada Syndrome: a systematic review and meta-analysis. Journal of Arrhythmia, 34(6), 587-597.</Citation></Reference><Reference><Citation>Tse, G., Gong, M., Meng, L., Wong, C. W., Georgopoulos, S., Bazoukis, G., Wong, M. C. S., Letsas, K. P., Vassiliou, V. S., Xia, Y., Baranchuk, A. M., Yan, G. X., & Liu, T. (2018). Meta-analysis of Tpeak-Tend and Tpeak-Tend/QT ratio for risk stratification in congenital long QT syndrome. Journal of Electrocardiology, 51(3), 396-401. https://doi.org/10.1016/j.jelectrocard.2018.03.001</Citation></Reference><Reference><Citation>Tse, G., Gong, M., Meng, L., Wong, C. W., Bazoukis, G., Chan, M. T. V., Wong, M. C. S., Letsas, K. P., Baranchuk, A., Yan, G. X., Liu, T., & Wu, W. K. K. (2018). Predictive value of Tpeak-Tend indices for adverse outcomes in acquired QT prolongation: A meta-analysis. Frontiers in Physiology, 9, 1226. https://doi.org/10.3389/fphys.2018.01226</Citation></Reference><Reference><Citation>Tse, G., Gong, M., Wong, W. T., Georgopoulos, S., Letsas, K. P., Vassiliou, V. S., Chan, Y. S., Yan, B. P., Wong, S. H., Wu, W. K. K., Ciobanu, A., Li, G., Shenthar, J., Saguner, A. M., Ali-Hasan-Al-Saegh, S., Bhardwaj, A., Sawant, A. C., Whittaker, P., Xia, Y., Yan, G. X., & Liu, T. (2017). The Tpeak− Tend interval as an electrocardiographic risk marker of arrhythmic and mortality outcomes: A systematic review and meta-analysis. Heart Rhythm: The Official Journal of the Heart Rhythm Society, 14(8), 1131-1137. https://doi.org/10.1016/j.hrthm.2017.05.031</Citation></Reference><Reference><Citation>Tse, G., & Yan, B. P. (2017). Traditional and novel electrocardiographic conduction and repolarization markers of sudden cardiac death. EP Europace, 19(5), 712-721. https://doi.org/10.1093/europace/euw280</Citation></Reference><Reference><Citation>Yan, G.-X., & Antzelevitch, C. (1998). Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation, 98(18), 1928-1936. https://doi.org/10.1161/01.CIR.98.18.1928</Citation></Reference><Reference><Citation>Yap, Y. G., & Camm, A. J. (2003). Drug induced QT prolongation and torsades de pointes. Heart, 89(11), 1363-1372. https://doi.org/10.1136/heart.89.11.1363</Citation></Reference><Reference><Citation>Yenerçağ, M., Arslan, U., Doğduş, M., Günal, Ö., Öztürk, Ç. E., Aksan, G., Erdoğan, G., Gül, S., Yontar, O. C., & Şen, A. (2020). Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19. Journal of Electrocardiology, 62, 5-9. https://doi.org/10.1016/j.jelectrocard.2020.07.005</Citation></Reference><Reference><Citation>Zabel, M., Portnoy, S., & Franz, M. R. (1995). Electrocardiographic indexes of dispersion of ventricular repolarization: An isolated heart validation study. Journal of the American College of Cardiology, 25(3), 746-752. https://doi.org/10.1016/0735-1097(94)00446-W</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000048 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000048 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33956361
|texte= The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33956361" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |